Orion Corporation, Orion Pharma: Parkinson Disease trials
The registry lists 11 Parkinson Disease studies with Orion Corporation, Orion Pharma as lead sponsor. 0 are open to participants now and 0 have results posted.
Phase 1 4Phase 2 4Phase 4 3(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Pharmacokinetic of Levodopa Study in Healthy MalesCompletedNCT03140956Phase 1
- Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Wearing-off (COMPOC)CompletedNCT02764125Phase 2
- Pharmacokinetic Study in Healthy VolunteersCompletedNCT02554734Phase 1
- Pharmacokinetic Study in Healthy MalesCompletedNCT02312232Phase 1
- Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Motor FluctuationsCompletedNCT01766258Phase 2
- Comparing Different Levodopa/Carbidopa/Entacapone Treatment RegimensCompletedNCT01296464Phase 2
- Levodopa Concentration Profile With Stalevo 75/125 mgCompletedNCT01070628Phase 1
- PET-Study: Effects of Single Doses of Stalevo and Levodopa/Carbidopa on Striatal 11C-Raclopride BindingTerminatedNCT00562198Phase 2
- Study to Evaluate Initiation of Stalevo in Early Wearing-offCompletedNCT00462007Phase 4
- Comtess® Versus Cabaseril® as Add-on to Levodopa in the Treatment of Parkinsonian Patients Suffering From Wearing- Off.CompletedNCT00247247Phase 4
- Stalevo in Early Wearing-Off PatientsCompletedNCT00125567Phase 4